Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q9BYK8
UPID:
HELZ2_HUMAN
Alternative names:
ATP-dependent helicase PRIC285; Helicase with zinc finger 2, transcriptional coactivator; PPAR-alpha-interacting complex protein 285; PPAR-gamma DNA-binding domain-interacting protein 1; Peroxisomal proliferator-activated receptor A-interacting complex 285 kDa protein
Alternative UPACC:
Q9BYK8; Q3C2G2; Q4VXQ1; Q8TEF3; Q96ND3; Q9C094
Background:
Helicase with zinc finger domain 2, known by alternative names such as ATP-dependent helicase PRIC285 and PPAR-gamma DNA-binding domain-interacting protein 1, plays a pivotal role as a transcriptional coactivator. It interacts with nuclear receptors including PPARA, PPARG, THRA, THRB, and RXRA, facilitating the transcription process.
Therapeutic significance:
Understanding the role of Helicase with zinc finger domain 2 could open doors to potential therapeutic strategies. Its interaction with key nuclear receptors highlights its importance in gene expression regulation, suggesting its potential in targeted therapy development.